JP2017506898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506898A5 JP2017506898A5 JP2016553505A JP2016553505A JP2017506898A5 JP 2017506898 A5 JP2017506898 A5 JP 2017506898A5 JP 2016553505 A JP2016553505 A JP 2016553505A JP 2016553505 A JP2016553505 A JP 2016553505A JP 2017506898 A5 JP2017506898 A5 JP 2017506898A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleases
- donor sequences
- composition
- target sequence
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943865P | 2014-02-24 | 2014-02-24 | |
| US61/943,865 | 2014-02-24 | ||
| PCT/US2015/017302 WO2015127439A1 (en) | 2014-02-24 | 2015-02-24 | Methods and compositions for nuclease-mediated targeted integration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165181A Division JP6788082B2 (ja) | 2014-02-24 | 2019-09-11 | ヌクレアーゼ媒介性標的化組み込みのための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506898A JP2017506898A (ja) | 2017-03-16 |
| JP2017506898A5 true JP2017506898A5 (cg-RX-API-DMAC7.html) | 2018-02-08 |
| JP6606088B2 JP6606088B2 (ja) | 2019-11-13 |
Family
ID=53879145
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553505A Expired - Fee Related JP6606088B2 (ja) | 2014-02-24 | 2015-02-24 | ヌクレアーゼ媒介性標的化組み込みのための方法および組成物 |
| JP2019165181A Expired - Fee Related JP6788082B2 (ja) | 2014-02-24 | 2019-09-11 | ヌクレアーゼ媒介性標的化組み込みのための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019165181A Expired - Fee Related JP6788082B2 (ja) | 2014-02-24 | 2019-09-11 | ヌクレアーゼ媒介性標的化組み込みのための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10370680B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3110454B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6606088B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015218576B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2939942A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015127439A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| GB2537000C (en) | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| CA2891347C (en) | 2012-12-06 | 2018-02-27 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| EP2958990B1 (en) | 2013-02-20 | 2019-10-16 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| KR20200136508A (ko) | 2013-04-16 | 2020-12-07 | 리제너론 파마슈티칼스 인코포레이티드 | 랫트 게놈의 표적화된 변형 |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| CN110713995B (zh) | 2013-10-17 | 2023-08-01 | 桑格摩生物科学股份有限公司 | 用于核酸酶介导的基因组工程改造的递送方法和组合物 |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| JP6174811B2 (ja) | 2013-12-11 | 2017-08-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ゲノムの標的改変のための方法及び組成物 |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3207124B1 (en) | 2014-10-15 | 2019-06-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US11667911B2 (en) | 2015-09-24 | 2023-06-06 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/CAS-mediated genome editing |
| SG11201803173VA (en) | 2015-10-23 | 2018-05-30 | Harvard College | Nucleobase editors and uses thereof |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| EP4047092B1 (en) | 2016-04-13 | 2025-07-30 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| NZ747857A (en) | 2016-05-20 | 2023-01-27 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide rnas |
| PL3272867T3 (pl) | 2016-06-02 | 2020-01-31 | Sigma-Aldrich Co. Llc | Wykorzystanie programowalnych białek wiążących dna w celu wzmocnienia celowanej modyfikacji genomu |
| SG11201901305YA (en) | 2016-07-29 | 2019-03-28 | Regeneron Pharma | Mice comprising mutations resulting in expression of c-truncated fibrillin-1 |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| KR102777514B1 (ko) | 2017-01-19 | 2025-03-06 | 옴니에이비 오퍼레이션스, 인코포레이티드 | 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체 |
| CA3049980A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| BR112020001364A2 (pt) | 2017-07-31 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | métodos para testar e modificar a capacidade de uma crispr/cas nuclease. |
| US20190032156A1 (en) | 2017-07-31 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
| WO2019028023A2 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| EP4276185A3 (en) | 2017-09-29 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| AU2018352592C1 (en) | 2017-10-16 | 2025-09-25 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3829652A4 (en) * | 2018-08-01 | 2022-05-11 | University of Maryland, Baltimore | MODULATION OF MTORC1 ACTIVITY AND AUTOPHAGY BY CIB2-RHEB INTERACTION |
| SG11202101576UA (en) | 2018-08-18 | 2021-03-30 | Harvard College | In situ gene editing |
| PL3867372T3 (pl) | 2018-10-16 | 2025-06-23 | Blueallele Corporation | Sposoby ukierunkowanego wprowadzania dna do genów |
| EP3867380A2 (en) | 2018-10-18 | 2021-08-25 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor ix |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB2601617B (en) | 2019-03-19 | 2024-02-21 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| EP3983435A4 (en) * | 2019-06-13 | 2023-03-08 | Allogene Therapeutics, Inc. | ANTI-TALEN ANTIBODIES AND THEIR USES |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| US20230020565A1 (en) * | 2019-12-04 | 2023-01-19 | Sangamo Therapeutics, Inc. | Novel compositions and methods for producing recombinant aav |
| CN115175559A (zh) | 2020-01-28 | 2022-10-11 | 瑞泽恩制药公司 | 包含人源化pnpla3基因座的非人动物及其使用方法 |
| WO2021158883A1 (en) | 2020-02-07 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized klkb1 locus and methods of use |
| US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| US20240415980A1 (en) | 2021-10-28 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| WO2023150623A2 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| JP2025514304A (ja) | 2022-04-29 | 2025-05-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定 |
| WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| WO2023235726A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr interference therapeutics for c9orf72 repeat expansion disease |
| WO2025029654A2 (en) | 2023-07-28 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU704601B2 (en) | 1994-01-18 | 1999-04-29 | Scripps Research Institute, The | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| AU723163B2 (en) | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6479626B1 (en) | 1998-03-02 | 2002-11-12 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| EP1236045B1 (en) | 1999-12-06 | 2005-11-09 | Sangamo Biosciences Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| CA2398590C (en) | 2000-02-08 | 2012-08-28 | Sangamo Biosciences, Inc. | Cells for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| SI1317559T1 (sl) | 2000-04-28 | 2009-04-30 | St Jude Childrens Res Hospital | Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna |
| WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US20050267061A1 (en) | 2004-04-08 | 2005-12-01 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| JP4968498B2 (ja) | 2002-01-23 | 2012-07-04 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | ジンクフィンガーヌクレアーゼを用いる、標的化された染色体変異誘発 |
| EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| US9447434B2 (en) | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| CA2562193A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| EP1735350B1 (en) * | 2004-04-15 | 2010-08-25 | Genencor International, Inc. | Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept |
| CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| MX2007013757A (es) | 2005-05-05 | 2008-01-24 | Univ Arizona | Reagrupacion permitida de secuencia (seer)-met odo de novedad para visualizar secuencias de adn especificas. |
| SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| US20070059833A1 (en) * | 2005-09-07 | 2007-03-15 | Maxcyte, Inc. | Use of Nucleases to Improve Viability and Enhance Transgene Expression in Transfected Cells |
| ES2533370T3 (es) | 2005-10-18 | 2015-04-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| ATE462783T1 (de) | 2006-05-25 | 2010-04-15 | Sangamo Biosciences Inc | Variante foki-spaltungshälften-domänen |
| EP2765195A1 (en) | 2006-05-25 | 2014-08-13 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
| WO2008060510A2 (en) * | 2006-11-13 | 2008-05-22 | Sangamo Biosciences, Inc. | Zinc finger nuclease for targeting the human glucocorticoid receptor locus |
| DE602008003684D1 (de) * | 2007-04-26 | 2011-01-05 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
| EP2171052B1 (en) | 2007-07-12 | 2014-08-27 | Sangamo BioSciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression |
| US9506120B2 (en) | 2007-09-27 | 2016-11-29 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
| AU2008317354B2 (en) | 2007-10-25 | 2014-04-10 | Ospedale San Raffaele S.R.L. | Methods and compositions for targeted integration |
| EP2281050B1 (en) | 2008-04-14 | 2014-04-02 | Sangamo BioSciences, Inc. | Linear donor constructs for targeted integration |
| CA2734235C (en) | 2008-08-22 | 2019-03-26 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| CA2756833C (en) | 2009-04-09 | 2019-11-19 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| JP2013500018A (ja) * | 2009-07-24 | 2013-01-07 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | ゲノム編集のための方法 |
| WO2011078665A1 (en) * | 2009-12-21 | 2011-06-30 | Keygene N.V. | Improved techniques for transfecting protoplasts |
| EP2615106B1 (en) | 2010-02-08 | 2018-04-25 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
| AU2011215557B2 (en) | 2010-02-09 | 2016-03-10 | Sangamo Therapeutics, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| AU2011219716A1 (en) * | 2010-02-26 | 2012-09-27 | Cellectis | Use of endonucleases for inserting transgenes into safe harbor loci |
| WO2011139336A1 (en) | 2010-04-26 | 2011-11-10 | Sangamo Biosciences, Inc. | Genome editing of a rosa locus using nucleases |
| EP2571512B1 (en) | 2010-05-17 | 2017-08-23 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| US9057057B2 (en) * | 2010-07-27 | 2015-06-16 | The Johns Hopkins University | Obligate heterodimer variants of foki cleavage domain |
| ES2562421T3 (es) | 2010-10-12 | 2016-03-04 | The Children's Hospital Of Philadelphia | Métodos y composiciones para tratar la hemofilia B |
| IL293650B2 (en) | 2011-09-21 | 2024-10-01 | Sangamo Therapeutics Inc | Methods and compositions for regulation of transgene expression |
| AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
| GB2537000C (en) * | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| AR091482A1 (es) * | 2012-06-21 | 2015-02-04 | Recombinetics Inc | Celulas modificadas geneticamente y metodos par su obtencion |
| SG11201500852WA (en) | 2012-08-29 | 2015-04-29 | Sangamo Biosciences Inc | Methods and compositions for treatment of a genetic condition |
| EP2929017A4 (en) | 2012-12-05 | 2016-09-28 | Sangamo Biosciences Inc | METHOD AND COMPOSITIONS FOR REGULATING METABOLISM DISEASES |
| WO2014186585A2 (en) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| CN110713995B (zh) * | 2013-10-17 | 2023-08-01 | 桑格摩生物科学股份有限公司 | 用于核酸酶介导的基因组工程改造的递送方法和组合物 |
| WO2015057976A1 (en) * | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| DK3080274T3 (da) | 2013-12-09 | 2020-08-31 | Sangamo Therapeutics Inc | Fremgangsmåder og sammensætninger til genom-manipulation |
-
2015
- 2015-02-24 CA CA2939942A patent/CA2939942A1/en active Pending
- 2015-02-24 US US14/630,128 patent/US10370680B2/en active Active
- 2015-02-24 EP EP15752803.5A patent/EP3110454B1/en not_active Not-in-force
- 2015-02-24 JP JP2016553505A patent/JP6606088B2/ja not_active Expired - Fee Related
- 2015-02-24 AU AU2015218576A patent/AU2015218576B2/en not_active Ceased
- 2015-02-24 WO PCT/US2015/017302 patent/WO2015127439A1/en not_active Ceased
-
2019
- 2019-08-05 US US16/531,749 patent/US11591622B2/en active Active
- 2019-09-11 JP JP2019165181A patent/JP6788082B2/ja not_active Expired - Fee Related
-
2022
- 2022-12-20 US US18/085,420 patent/US20230203540A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506898A5 (cg-RX-API-DMAC7.html) | ||
| JP2016539627A5 (cg-RX-API-DMAC7.html) | ||
| WO2017066497A3 (en) | Genome engineering with type i crispr systems in eukaryotic cells | |
| HK1258900A1 (zh) | 递送方法和组合物 | |
| WO2017004279A3 (en) | Compositions comprising nucleic acids and methods of using the same | |
| JP2016518142A5 (cg-RX-API-DMAC7.html) | ||
| EP4253551A3 (en) | Novel crispr dna and rna targeting enzymes and systems | |
| WO2017100431A3 (en) | Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy | |
| JP2016501531A5 (cg-RX-API-DMAC7.html) | ||
| WO2018015936A3 (en) | Methods and compositions for modifying genomic dna | |
| JP2016537982A5 (cg-RX-API-DMAC7.html) | ||
| MX2021014368A (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
| EP4361261A3 (en) | Novel cas13b orthologues crispr enzymes and systems | |
| WO2019006471A3 (en) | NOVEL CRISPR RNA TARGETING ENZYMES, SYSTEMS AND USES THEREOF | |
| JP2016512691A5 (cg-RX-API-DMAC7.html) | ||
| MX377162B (es) | Nuevas enzimas y sistemas crispr | |
| WO2016100955A3 (en) | Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins | |
| WO2016172632A3 (en) | Amplification with primers of limited nucleotide composition | |
| WO2016183402A3 (en) | Methods of making and using guide rna for use with cas9 systems | |
| EP4400597A3 (en) | Novel rna-guided nucleases and uses thereof | |
| RU2019114217A (ru) | Геномная инженерия | |
| WO2016025131A8 (en) | Genetic targeting in non-conventional yeast using an rna-guided endonuclease | |
| GB2569733A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| GB2542653A (en) | Methods and compositions for treating cells for transplant |